SCHEMBL7667435

SCHEMBL7667435

Cc1ccc2c(c1)Sc1sc3ccccc3c1C(=O)N2

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 8/20 0.47
▸ MEN1 O00255 7/20 0.47
▸ KMT2A Q03164 7/20 0.47
▸ GAA P10253 5/20 0.47
▸ TDP1 Q9NUW8 3/20 0.47
▸ NPC1 O15118 2/20 0.47
▸ RAB9A P51151 2/20 0.47
▸ NOX1 Q9Y5S8 1/20 0.47
▸ POLB P06746 3/20 0.45
▸ DUSP3 P51452 1/20 0.45
▸ BLM P54132 1/20 0.45
▸ PTPN5 P54829 1/20 0.45
▸ PTPN11 Q06124 1/20 0.45
▸ MCL1 Q07820 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.42
▸ L3MBTL1 Q9Y468 2/20 0.42
▸ ROS1 P08922 1/20 0.40
▸ CDK5 Q00535 1/20 0.40
▸ ACVR1 Q04771 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7658840 0.85 NOX1 (0.48) MAPTMEN1KMT2AGAATDP1
SCHEMBL7663629 0.84 L3MBTL1 (0.49) MAPTMEN1KMT2AGAATDP1
SCHEMBL6994996 0.76 CSNK1G1 (0.50) MAPTMEN1KMT2AGAATDP1
SCHEMBL6998420 0.76 CSNK1G1 (0.50) MAPTMEN1KMT2AGAATDP1
SCHEMBL7668794 0.73 MAPT (0.44) MAPTMEN1KMT2ATDP1RAB9A
SCHEMBL7662214 0.72 EPHX2 (0.42) MAPTMEN1KMT2AGAATDP1
SCHEMBL6992029 0.68 ACVR1 (0.48) MAPTMEN1KMT2AGAATDP1
SCHEMBL6998771 0.68 CDK5 (0.48) MAPTMEN1KMT2AGAATDP1
SCHEMBL29640485 0.66 MAPT (0.59) MAPTMEN1KMT2AGAATDP1
SCHEMBL225916 0.66 MAPT (0.59) MAPTMEN1KMT2AGAATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 — — US claimed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 — — US claimed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 — — EP claimed
US-6455521-B1 PSYCHOLOGICAL DISORDERS; SIDE EFFECT REDUCTION MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 — — US disclosed
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof MITSUBISHI PHARMA CORPORATION (JP) 2002-04-11 — — US disclosed
US-6271225-B1 PSYCHOLOGICAL DISORDERS WELFIDE CORPORATION (JP) 2001-08-07 — — US disclosed
EP-1016664-A1 FUSED THIOPHENE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-07-05 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042411-A1 Condensed thiophene compounds and pharmaceutical use thereof ACIN1, ACHE, TPMT MAPT 15/4885MEN1 1756/4885KMT2A 2923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback